Coya Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.4%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$1.48next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 11 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Collaboration Revenue Annually8M
Cash and Cash Equivalents Quarterly51M
Watch Items
- ALSTARS Phase 2 trial enrollment completion for COYA 302 in ALSTrigger: Full enrollment of the trialAction: Monitor corporate updates and press releases for enrollment completion announcements expected in 2H 2026.
- Initiation of Phase 2a clinical study evaluating COYA 302 in Frontotemporal Dementia (FTD)Trigger: First patient dosed / trial initiationAction: Track regulatory filings and clinical trial registries for the start of the Phase 2a trial expected in 2H 2026.
- Cash runway sustainabilityTrigger: Cash levels dropping below 12 months of operating expensesAction: Evaluate quarterly cash burn rates against the stated runway extending into the second half of 2027.
Research as of 19 Jun 2026